The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants.
So far the government has distributed about 300,000 doses of Evusheld, a new drug that protects against COVID-19. Some 7 million Americans could benefit from the drug right away.
Georgians still have access to monoclonal antibody infusions despite a recent change in the distribution model, Gov. Brian Kemp said during a briefing at the state Capitol on Thursday. And DPH Commissioner Dr. Kathleen Toomey said fully vaccinated Georgians who feel they are at risk should consider getting a booster shot if they were fully vaccinated with the Pfizer brand.
About 70 percent of these lab-created drugs are being used in the Southeast. With that uneven distribution, federal health officials recently decided to take over supplies and allocate them through state agencies.
Dalton’s new Regeneron treatment drive-in clinic helped about 60 people receive Regeneron’s monoclonal antibody treatment for early diagnosed COVID-19 cases. The city council believes this clinic is the first of its kind in Georgia.
Monoclonal antibodies can be used to treat people with mild to moderate COVID-19, but the treatment doesn't work for those who've already developed more severe symptoms or are hospitalized.
Drugs that can help keep COVID-19 patients out of the hospital are playing only a small role in Michigan, where the pandemic is accelerating. Logistical challenges are to blame.
Researchers are reporting some progress in their search for drugs that tamp down the overwhelming immune reaction that can kill a patient with COVID-19.
Drugs for COVID-19 are sorted into three basic categories: They work, they don't work, or there simply isn't enough information to know. A generic steroid is one medicine that proved helpful.
Antibody-based drugs that bind to the coronavirus to prevent it from invading cells can help patients with mild to moderate COVID-19. But the medicines can be tough to find in time.
While logistical challenges have hampered use of antibody drugs to treat people with mild-to-moderate COVID-19, recent results show the medicines can be worthwhile.
Monoclonal antibodies to prevent severe COVID-19 aren't being used as widely as expected. Medical staff shortages and patient transportation problems are two of the reasons.
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.
Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.
